New evidence sharpens the outlook for ocular FIP treatment

Ocular feline infectious peritonitis is coming into sharper focus as new evidence suggests antiviral treatment can reverse many eye lesions, even in cats with advanced disease. The most direct new data come from a 2025 observational case series in the Journal of Veterinary Internal Medicine, which reported that FIP-associated uveitis responded effectively in 82% of treated cats. The report is notable because ocular disease has often been discussed alongside neurologic FIP as a harder-to-treat form, but published clinical detail on eye-specific response has been comparatively limited. (pubmed.ncbi.nlm.nih.gov)

That shift is happening against a broader change in FIP care. For years, many U.S. veterinarians and pet parents were navigating a disease once considered almost uniformly fatal while relying on unregulated antiviral products. In May 2024, FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat with FIP under GFI #256, while also stressing that these compounded drugs remain unapproved and are not technically “legal” in the fully approved-drug sense. Shortly after, Stokes Pharmacy and Bova announced a compounded oral GS-441524 product that became available in the U.S. on June 1, 2024, giving clinicians a more structured prescribing route. (fda.gov)

The new ocular case series evaluated 20 cats with FIP and ocular involvement treated with injectable remdesivir, oral GS-441524, or both. According to the abstract and figure details, treatment protocols included remdesivir at 15 to 20 mg/kg or 10 to 14 mg/kg and oral GS-441524 at 15 to 22 mg/kg or 10 to 14 mg/kg, depending on the case. The authors reported improvement in ocular inflammation, including uveitis, and documented examples of rapid clinical response, with one cat showing marked improvement in iris color change after three days of intravenous remdesivir. At least one cat, however, required ongoing management for unilateral secondary glaucoma, a reminder that viral control doesn’t always erase downstream ocular morbidity. Vet-focused education around the paper has also underscored how varied these cases can look at presentation: anterior chamber findings may include keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, or fibrinous exudate, while posterior segment disease may show tapetal or nontapetal lesions, retinal hemorrhage or vascular tortuosity, retinal detachment, or perivascular cuffing. In some cats, ocular signs are bilateral; in others, the eye exam is the first major clue to systemic FIP. (pubmed.ncbi.nlm.nih.gov)

The broader literature helps explain why this matters. The 2025 ABCD FIP guideline notes earlier evidence that cats with neurologic and ocular signs often require higher doses than uncomplicated effusive cases, and it cites prior reports of return of vision and ocular improvement within weeks of GS-441524 treatment. Practical reviews and podcasts aimed at clinicians have reinforced the same point: the traditional 12-week antiviral course is still common, but eyes and the central nervous system are treated as harder-to-penetrate sites, so dose escalation and sometimes longer treatment periods may be needed. Those same discussions also caution that many cats look dramatically better within about the first week of therapy, yet early appetite and weight gain do not necessarily mean viral clearance. A large 2026 Scientific Reports analysis of 629 treated cats similarly found that positive outcomes depended on timely intervention, dose adjustments, and extended treatment periods, particularly in cats with neurologic and ocular signs. Together, those sources suggest ocular FIP is treatable, but not necessarily with a one-size-fits-all protocol. (abcdcatsvets.org)

Industry and clinical education channels are reinforcing the same message. VetGirl’s recent FIP podcast coverage has focused not just on ocular disease and dosing adjustments, but also on the need for more objective ways to decide when treatment can safely stop. In discussion of a 2025 JSAP study, the podcast highlighted interest in tracking acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, along with the albumin:globulin ratio, rather than relying only on visible clinical improvement. Cornell’s Feline Health Center has also framed the U.S. availability of compounded GS-441524 as a major change for practitioners and pet parents, especially given the years when desperate families turned to black-market sources of uncertain quality. That concern is supported by published research showing variability in unregulated antiviral products, a safety and efficacy issue that has shaped clinician caution around FIP treatment for years. (vet.cornell.edu)

The diagnostic side remains challenging, even as treatment has improved. Continuing education and podcast discussions aimed at clinicians have emphasized that FIP is still usually a presumptive diagnosis in practice, built from signalment, clinicopathologic patterns, imaging, effusion analysis when present, and compatible organ involvement rather than a single easy confirmatory test. That matters for ocular cases because dry FIP can present subtly, and eye findings may be what elevate FIP on the differential list before more classic systemic signs are obvious.

Why it matters: For veterinary professionals, ocular FIP is a diagnostic and pharmacologic issue, not just an ophthalmic one. Eye findings such as anterior uveitis, keratic precipitates, iris color change, chorioretinitis, retinal vascular changes, or secondary glaucoma may be among the clues that push a dry FIP case higher on the differential list. Once suspected, those cases may warrant faster escalation to antiviral planning, closer ophthalmic monitoring, and more detailed conversations with pet parents about dose intensity, treatment duration, relapse risk, and the possibility that some structural damage may persist even after systemic improvement. The practical takeaway is that ocular involvement should no longer be read as hopeless, but it should still be read as higher complexity. (pubmed.ncbi.nlm.nih.gov)

There’s also a workflow implication. FDA’s 2024 enforcement-discretion position created a patient-specific prescribing pathway, but not office-stock flexibility for GS-441524 unless separately nominated, which means clinics still need to plan around diagnosis, prescription logistics, pharmacy access, and follow-up. In real practice, that can affect how quickly treatment starts, especially in unstable cats or referral settings. As more pharmacies, clinical protocols, and published datasets come online, the field may move toward more standardized ocular and neurologic FIP algorithms, but it isn’t fully there yet. (fda.gov)

What to watch: The next phase will likely center on larger prospective studies, clearer dose recommendations for ocular versus neurologic disease, and stronger guidance on when cats need combination therapy, longer courses, or rescue protocols after incomplete response or relapse. Expect growing attention as well to treatment-stop criteria that incorporate biomarker trends, including acute phase proteins and the albumin:globulin ratio, so clinicians are not forced to rely only on the fact that a cat looks better early in therapy. (abcdcatsvets.org)